A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study
To compare a single infusion of the anti-TNF antibody infliximab vs CSs for acute panuveitis attacks in Behçet's disease (BD). A prospective, observational study of patients with panuveitis, who received either an infliximab infusion (5 mg/kg, 19 eyes) or high-dose methylprednisolone intravenou...
Gespeichert in:
| Veröffentlicht in: | Rheumatology (Oxford, England) England), 2011-03, Vol.50 (3), p.593-597 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 597 |
|---|---|
| container_issue | 3 |
| container_start_page | 593 |
| container_title | Rheumatology (Oxford, England) |
| container_volume | 50 |
| creator | MARKOMICHELAKIS, Nikos DELICHA, Evi MASSELOS, Stylianos FRAGIADAKI, Kalliopi KAKLAMANIS, Phaedon SFIKAKIS, Petros P |
| description | To compare a single infusion of the anti-TNF antibody infliximab vs CSs for acute panuveitis attacks in Behçet's disease (BD).
A prospective, observational study of patients with panuveitis, who received either an infliximab infusion (5 mg/kg, 19 eyes) or high-dose methylprednisolone intravenously (1 g/day for 3 days, 8 eyes), or intra-vitreal triamcinolone acetonide (4 mg, 8 eyes) at attack's onset. Baseline maintenance therapy remained unchanged during the following 30 days. Visual acuity, anterior chamber cells, vitreous cells and inflammation of the posterior eye segment were assessed at baseline and at Days 1, 7, 14 and 29 (±1) post-treatment.
While no significant differences were noted between i.v. and intra-vitreal CSs, infliximab was faster than CSs in decreasing total ocular inflammation scores and fundus inflammation scores (P = 0.01 and P |
| doi_str_mv | 10.1093/rheumatology/keq366 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_853473927</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>853473927</sourcerecordid><originalsourceid>FETCH-LOGICAL-c445t-200bdf6635c8e10d477c0edc28c863b84ef63b3dbb1e384319b32a9899c3d92f3</originalsourceid><addsrcrecordid>eNpNkM1u1DAUhS0EoqXwBEjIG9RVqO3rSWx2bcWfVIkNrCPHvmnNJPHU1xmYBc_TB-mLkWqGwuqcxXfO4mPstRTvpLBwlm9wHl1JQ7rena3xFur6CTuWulaVAFBPH7vSR-wF0Q8hxEqCec6O1HLQmKY5Zr_POcXpekAep36Iv-Louoc6U0wT3xL3KZfoExXMKQbifcrc-bkg37hp3mIskbgrxfk1LUN-gTf3d1hOiYdI6Ajfc7ecjBuXXYlb5Lr6ibjmVOawe8me9W4gfHXIE_b944dvl5-rq6-fvlyeX1Ve61WplBBd6OsaVt6gFEE3jRcYvDLe1NAZjf0SELpOIhgN0nagnDXWeghW9XDCTve_m5xuZ6TSjpE8DoObMM3UmhXoBqxqFhL2pM-JKGPfbvLiJO9aKdoH7e3_2tu99mX15vA_dyOGx81fzwvw9gA48m7os5t8pH8cWADZWPgDaDOTEw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>853473927</pqid></control><display><type>article</type><title>A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study</title><source>MEDLINE</source><source>Oxford University Press Journals Current</source><source>Alma/SFX Local Collection</source><creator>MARKOMICHELAKIS, Nikos ; DELICHA, Evi ; MASSELOS, Stylianos ; FRAGIADAKI, Kalliopi ; KAKLAMANIS, Phaedon ; SFIKAKIS, Petros P</creator><creatorcontrib>MARKOMICHELAKIS, Nikos ; DELICHA, Evi ; MASSELOS, Stylianos ; FRAGIADAKI, Kalliopi ; KAKLAMANIS, Phaedon ; SFIKAKIS, Petros P</creatorcontrib><description>To compare a single infusion of the anti-TNF antibody infliximab vs CSs for acute panuveitis attacks in Behçet's disease (BD).
A prospective, observational study of patients with panuveitis, who received either an infliximab infusion (5 mg/kg, 19 eyes) or high-dose methylprednisolone intravenously (1 g/day for 3 days, 8 eyes), or intra-vitreal triamcinolone acetonide (4 mg, 8 eyes) at attack's onset. Baseline maintenance therapy remained unchanged during the following 30 days. Visual acuity, anterior chamber cells, vitreous cells and inflammation of the posterior eye segment were assessed at baseline and at Days 1, 7, 14 and 29 (±1) post-treatment.
While no significant differences were noted between i.v. and intra-vitreal CSs, infliximab was faster than CSs in decreasing total ocular inflammation scores and fundus inflammation scores (P = 0.01 and P < 0.0001 for treatment × time(2) interaction, respectively, using generalized estimating equation analysis). Independently of time, infliximab was superior to CSs in clearing retinal vasculitis (P < 0.003), as well as in resolution of retinitis (P = 0.008) and cystoid macular oedema (P < 0.007). Moreover, a faster regression of cystoid macular oedema was observed with infliximab compared with CSs (P < 0.03). The beneficial effects of the three treatment modalities on visual acuity were comparable from baseline to the end of follow-up. No side effects were noted with infliximab or methylprednisolone, whereas intra-vitreal triamcinolone acetonide caused ocular hypertension in four of the eight eyes, requiring surgical intervention in two.
A single infusion of infliximab should always be considered, even as an adjunct therapy, for the control of acute panuveitis attacks in BD.</description><identifier>ISSN: 1462-0324</identifier><identifier>EISSN: 1462-0332</identifier><identifier>DOI: 10.1093/rheumatology/keq366</identifier><identifier>PMID: 21097877</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Adult ; Anti-Inflammatory Agents - administration & dosage ; Antibodies, Monoclonal - administration & dosage ; Behcet Syndrome - complications ; Behcet Syndrome - drug therapy ; Biological and medical sciences ; Bones, joints and connective tissue. Antiinflammatory agents ; Diseases of the osteoarticular system ; Female ; Humans ; Infliximab ; Infusions, Intravenous ; Intravitreal Injections ; Male ; Medical sciences ; Methylprednisolone - administration & dosage ; Ophthalmology ; Pharmacology. Drug treatments ; Treatment Outcome ; Triamcinolone - administration & dosage ; Uvea diseases ; Uveitis - drug therapy ; Uveitis - etiology ; Young Adult</subject><ispartof>Rheumatology (Oxford, England), 2011-03, Vol.50 (3), p.593-597</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c445t-200bdf6635c8e10d477c0edc28c863b84ef63b3dbb1e384319b32a9899c3d92f3</citedby><cites>FETCH-LOGICAL-c445t-200bdf6635c8e10d477c0edc28c863b84ef63b3dbb1e384319b32a9899c3d92f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23933179$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21097877$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MARKOMICHELAKIS, Nikos</creatorcontrib><creatorcontrib>DELICHA, Evi</creatorcontrib><creatorcontrib>MASSELOS, Stylianos</creatorcontrib><creatorcontrib>FRAGIADAKI, Kalliopi</creatorcontrib><creatorcontrib>KAKLAMANIS, Phaedon</creatorcontrib><creatorcontrib>SFIKAKIS, Petros P</creatorcontrib><title>A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study</title><title>Rheumatology (Oxford, England)</title><addtitle>Rheumatology (Oxford)</addtitle><description>To compare a single infusion of the anti-TNF antibody infliximab vs CSs for acute panuveitis attacks in Behçet's disease (BD).
A prospective, observational study of patients with panuveitis, who received either an infliximab infusion (5 mg/kg, 19 eyes) or high-dose methylprednisolone intravenously (1 g/day for 3 days, 8 eyes), or intra-vitreal triamcinolone acetonide (4 mg, 8 eyes) at attack's onset. Baseline maintenance therapy remained unchanged during the following 30 days. Visual acuity, anterior chamber cells, vitreous cells and inflammation of the posterior eye segment were assessed at baseline and at Days 1, 7, 14 and 29 (±1) post-treatment.
While no significant differences were noted between i.v. and intra-vitreal CSs, infliximab was faster than CSs in decreasing total ocular inflammation scores and fundus inflammation scores (P = 0.01 and P < 0.0001 for treatment × time(2) interaction, respectively, using generalized estimating equation analysis). Independently of time, infliximab was superior to CSs in clearing retinal vasculitis (P < 0.003), as well as in resolution of retinitis (P = 0.008) and cystoid macular oedema (P < 0.007). Moreover, a faster regression of cystoid macular oedema was observed with infliximab compared with CSs (P < 0.03). The beneficial effects of the three treatment modalities on visual acuity were comparable from baseline to the end of follow-up. No side effects were noted with infliximab or methylprednisolone, whereas intra-vitreal triamcinolone acetonide caused ocular hypertension in four of the eight eyes, requiring surgical intervention in two.
A single infusion of infliximab should always be considered, even as an adjunct therapy, for the control of acute panuveitis attacks in BD.</description><subject>Adult</subject><subject>Anti-Inflammatory Agents - administration & dosage</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Behcet Syndrome - complications</subject><subject>Behcet Syndrome - drug therapy</subject><subject>Biological and medical sciences</subject><subject>Bones, joints and connective tissue. Antiinflammatory agents</subject><subject>Diseases of the osteoarticular system</subject><subject>Female</subject><subject>Humans</subject><subject>Infliximab</subject><subject>Infusions, Intravenous</subject><subject>Intravitreal Injections</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Methylprednisolone - administration & dosage</subject><subject>Ophthalmology</subject><subject>Pharmacology. Drug treatments</subject><subject>Treatment Outcome</subject><subject>Triamcinolone - administration & dosage</subject><subject>Uvea diseases</subject><subject>Uveitis - drug therapy</subject><subject>Uveitis - etiology</subject><subject>Young Adult</subject><issn>1462-0324</issn><issn>1462-0332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkM1u1DAUhS0EoqXwBEjIG9RVqO3rSWx2bcWfVIkNrCPHvmnNJPHU1xmYBc_TB-mLkWqGwuqcxXfO4mPstRTvpLBwlm9wHl1JQ7rena3xFur6CTuWulaVAFBPH7vSR-wF0Q8hxEqCec6O1HLQmKY5Zr_POcXpekAep36Iv-Louoc6U0wT3xL3KZfoExXMKQbifcrc-bkg37hp3mIskbgrxfk1LUN-gTf3d1hOiYdI6Ajfc7ecjBuXXYlb5Lr6ibjmVOawe8me9W4gfHXIE_b944dvl5-rq6-fvlyeX1Ve61WplBBd6OsaVt6gFEE3jRcYvDLe1NAZjf0SELpOIhgN0nagnDXWeghW9XDCTve_m5xuZ6TSjpE8DoObMM3UmhXoBqxqFhL2pM-JKGPfbvLiJO9aKdoH7e3_2tu99mX15vA_dyOGx81fzwvw9gA48m7os5t8pH8cWADZWPgDaDOTEw</recordid><startdate>20110301</startdate><enddate>20110301</enddate><creator>MARKOMICHELAKIS, Nikos</creator><creator>DELICHA, Evi</creator><creator>MASSELOS, Stylianos</creator><creator>FRAGIADAKI, Kalliopi</creator><creator>KAKLAMANIS, Phaedon</creator><creator>SFIKAKIS, Petros P</creator><general>Oxford University Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110301</creationdate><title>A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study</title><author>MARKOMICHELAKIS, Nikos ; DELICHA, Evi ; MASSELOS, Stylianos ; FRAGIADAKI, Kalliopi ; KAKLAMANIS, Phaedon ; SFIKAKIS, Petros P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c445t-200bdf6635c8e10d477c0edc28c863b84ef63b3dbb1e384319b32a9899c3d92f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Anti-Inflammatory Agents - administration & dosage</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Behcet Syndrome - complications</topic><topic>Behcet Syndrome - drug therapy</topic><topic>Biological and medical sciences</topic><topic>Bones, joints and connective tissue. Antiinflammatory agents</topic><topic>Diseases of the osteoarticular system</topic><topic>Female</topic><topic>Humans</topic><topic>Infliximab</topic><topic>Infusions, Intravenous</topic><topic>Intravitreal Injections</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Methylprednisolone - administration & dosage</topic><topic>Ophthalmology</topic><topic>Pharmacology. Drug treatments</topic><topic>Treatment Outcome</topic><topic>Triamcinolone - administration & dosage</topic><topic>Uvea diseases</topic><topic>Uveitis - drug therapy</topic><topic>Uveitis - etiology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MARKOMICHELAKIS, Nikos</creatorcontrib><creatorcontrib>DELICHA, Evi</creatorcontrib><creatorcontrib>MASSELOS, Stylianos</creatorcontrib><creatorcontrib>FRAGIADAKI, Kalliopi</creatorcontrib><creatorcontrib>KAKLAMANIS, Phaedon</creatorcontrib><creatorcontrib>SFIKAKIS, Petros P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Rheumatology (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MARKOMICHELAKIS, Nikos</au><au>DELICHA, Evi</au><au>MASSELOS, Stylianos</au><au>FRAGIADAKI, Kalliopi</au><au>KAKLAMANIS, Phaedon</au><au>SFIKAKIS, Petros P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study</atitle><jtitle>Rheumatology (Oxford, England)</jtitle><addtitle>Rheumatology (Oxford)</addtitle><date>2011-03-01</date><risdate>2011</risdate><volume>50</volume><issue>3</issue><spage>593</spage><epage>597</epage><pages>593-597</pages><issn>1462-0324</issn><eissn>1462-0332</eissn><abstract>To compare a single infusion of the anti-TNF antibody infliximab vs CSs for acute panuveitis attacks in Behçet's disease (BD).
A prospective, observational study of patients with panuveitis, who received either an infliximab infusion (5 mg/kg, 19 eyes) or high-dose methylprednisolone intravenously (1 g/day for 3 days, 8 eyes), or intra-vitreal triamcinolone acetonide (4 mg, 8 eyes) at attack's onset. Baseline maintenance therapy remained unchanged during the following 30 days. Visual acuity, anterior chamber cells, vitreous cells and inflammation of the posterior eye segment were assessed at baseline and at Days 1, 7, 14 and 29 (±1) post-treatment.
While no significant differences were noted between i.v. and intra-vitreal CSs, infliximab was faster than CSs in decreasing total ocular inflammation scores and fundus inflammation scores (P = 0.01 and P < 0.0001 for treatment × time(2) interaction, respectively, using generalized estimating equation analysis). Independently of time, infliximab was superior to CSs in clearing retinal vasculitis (P < 0.003), as well as in resolution of retinitis (P = 0.008) and cystoid macular oedema (P < 0.007). Moreover, a faster regression of cystoid macular oedema was observed with infliximab compared with CSs (P < 0.03). The beneficial effects of the three treatment modalities on visual acuity were comparable from baseline to the end of follow-up. No side effects were noted with infliximab or methylprednisolone, whereas intra-vitreal triamcinolone acetonide caused ocular hypertension in four of the eight eyes, requiring surgical intervention in two.
A single infusion of infliximab should always be considered, even as an adjunct therapy, for the control of acute panuveitis attacks in BD.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>21097877</pmid><doi>10.1093/rheumatology/keq366</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-0324 |
| ispartof | Rheumatology (Oxford, England), 2011-03, Vol.50 (3), p.593-597 |
| issn | 1462-0324 1462-0332 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_853473927 |
| source | MEDLINE; Oxford University Press Journals Current; Alma/SFX Local Collection |
| subjects | Adult Anti-Inflammatory Agents - administration & dosage Antibodies, Monoclonal - administration & dosage Behcet Syndrome - complications Behcet Syndrome - drug therapy Biological and medical sciences Bones, joints and connective tissue. Antiinflammatory agents Diseases of the osteoarticular system Female Humans Infliximab Infusions, Intravenous Intravitreal Injections Male Medical sciences Methylprednisolone - administration & dosage Ophthalmology Pharmacology. Drug treatments Treatment Outcome Triamcinolone - administration & dosage Uvea diseases Uveitis - drug therapy Uveitis - etiology Young Adult |
| title | A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T09%3A35%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20single%20infliximab%20infusion%20vs%20corticosteroids%20for%20acute%20panuveitis%20attacks%20in%20Beh%C3%A7et's%20disease:%20a%20comparative%204-week%20study&rft.jtitle=Rheumatology%20(Oxford,%20England)&rft.au=MARKOMICHELAKIS,%20Nikos&rft.date=2011-03-01&rft.volume=50&rft.issue=3&rft.spage=593&rft.epage=597&rft.pages=593-597&rft.issn=1462-0324&rft.eissn=1462-0332&rft_id=info:doi/10.1093/rheumatology/keq366&rft_dat=%3Cproquest_cross%3E853473927%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=853473927&rft_id=info:pmid/21097877&rfr_iscdi=true |